A recent cost-effectiveness analysis evaluated treatments for relapsed or refractory multiple myeloma from a United States health system perspective.
Higher scores on a multi-biomarker disease activity system are associated with hospital infection, myocardial infarction, and coronary heart disease events in older patients with rheumatoid arthritis.
Lung cancer screening based on individual risk may save more lives than current USPSTF estimations but is less efficient in terms of cost and quality of life-years gained.
A comparative effectiveness study analyzed usual care versus multilevel, multicomponent implementation strategies for blood pressure control in patients with hypertension.
The NCCN has issued updates to their guidelines for Hodgkin lymphoma, including additions to maintenance therapy options, systemic therapy options, and various treatment algorithms.
Results of a recent analysis showed that only three drug indications of six immuno-oncology agents met the durable survival threshold in the ASCO value framework.
A recent study identified patient characteristics that help predict poor 3-year survival in newly diagnosed standard-risk multiple myeloma.
Adjuvant EGFR TKI treatment for patients with EGFR-mutant NSCLC after complete resection offers a significant disease-free survival advantage, according to a recent meta-analysis.
High levels of a specific enzyme are linked with lower survival rates in patients with multiple myeloma, according to a new study.
Vaccine-based immunotherapy after surgery or radiotherapy did not increase survival in patients with localized non-small-cell lung cancer, according to a recent meta-analysis.